Katrien Stouffs1, Sari Daelemans2, Samuel Santos-Ribeiro2, Sara Seneca3, Alexander Gheldof3, Ali Sami Gürbüz4, Michel De Vos2, Herman Tournaye2, Christophe Blockeel2. 1. Center for Medical Genetics/Research Center Reproduction and Genetics, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090, Brussels, Belgium. katrien.Stouffs@uzbrussel.be. 2. Center for Reproductive Medicine, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Laarbeeklaan 101, 1090, Brussels, Belgium. 3. Center for Medical Genetics/Research Center Reproduction and Genetics, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel (VUB), Laarbeeklaan 101, 1090, Brussels, Belgium. 4. Novafertil IVF Center Yeni Meram Yolu No:75 Meram, 42090, Konya, Turkey.
Abstract
PURPOSE: We aim to investigate whether there is a genetic predisposition in women who developed ovarian hyperstimulation syndrome (OHSS) after GnRH antagonist protocol with GnRH agonist trigger and freeze-all approach. METHODS: Four patients with OHSS after GnRH agonist trigger and freeze-all approach were gathered from the worldwide patient population. These patients were analyzed through Whole Exome Sequencing. In this study known causes of OHSS were investigated and new causes present in at least two individuals were searched for. RESULTS: In the first part of the study, we evaluated the presence of mutations in genes already known to be involved in OHSS. In PGR and TP53, heterozygous alterations were detected. PGR is predicted to be involved in progesterone resistance with a recessive inheritance pattern and is, therefore, not considered as being causal. The consequences of the variant detected in TP53 currently remain unknown. In part 2 of the study, we assessed the clinical significance of variants in genes previously not linked to OHSS. We especially focused on genes with variants present in ≥ 2 patients. Two patients have variants in the FLT4 gene. Mutations in this gene are linked to hereditary lymphedema, but no link to OHSS has been described. CONCLUSIONS: Defining a genetic predisposition for OHSS is essential in view of prevention. In this study, a potential link between the FLT4 gene and OHSS has been suggested. Future functional studies are essential to define a more precise involvement of the detected variants in the development of OHSS.
PURPOSE: We aim to investigate whether there is a genetic predisposition in women who developed ovarian hyperstimulation syndrome (OHSS) after GnRH antagonist protocol with GnRH agonist trigger and freeze-all approach. METHODS: Four patients with OHSS after GnRH agonist trigger and freeze-all approach were gathered from the worldwide patient population. These patients were analyzed through Whole Exome Sequencing. In this study known causes of OHSS were investigated and new causes present in at least two individuals were searched for. RESULTS: In the first part of the study, we evaluated the presence of mutations in genes already known to be involved in OHSS. In PGR and TP53, heterozygous alterations were detected. PGR is predicted to be involved in progesterone resistance with a recessive inheritance pattern and is, therefore, not considered as being causal. The consequences of the variant detected in TP53 currently remain unknown. In part 2 of the study, we assessed the clinical significance of variants in genes previously not linked to OHSS. We especially focused on genes with variants present in ≥ 2 patients. Two patients have variants in the FLT4 gene. Mutations in this gene are linked to hereditary lymphedema, but no link to OHSS has been described. CONCLUSIONS: Defining a genetic predisposition for OHSS is essential in view of prevention. In this study, a potential link between the FLT4 gene and OHSS has been suggested. Future functional studies are essential to define a more precise involvement of the detected variants in the development of OHSS.
Authors: Jeffrey W Walter; Paula E North; Milton Waner; Adam Mizeracki; Francine Blei; John W T Walker; John F Reinisch; Douglas A Marchuk Journal: Genes Chromosomes Cancer Date: 2002-03 Impact factor: 5.006
Authors: Francisco J Morón; Francisco de Castro; Jose L Royo; Luis Montoro; Emilia Mira; María E Sáez; Luis M Real; Alejandro González; Santos Mañes; Agustín Ruiz Journal: Pharmacogenet Genomics Date: 2006-07 Impact factor: 2.089
Authors: T Mäkinen; L Jussila; T Veikkola; T Karpanen; M I Kettunen; K J Pulkkanen; R Kauppinen; D G Jackson; H Kubo; S Nishikawa; S Ylä-Herttuala; K Alitalo Journal: Nat Med Date: 2001-02 Impact factor: 53.440
Authors: Sérgio Reis Soares; Raúl Gómez; Carlos Simón; Juan Antonio García-Velasco; Antonio Pellicer Journal: Hum Reprod Update Date: 2008-04-02 Impact factor: 15.610
Authors: L Borgwardt; K W Olsen; M Rossing; R Borup Helweg-Larsen; M Toftager; A Pinborg; J Bogstad; K Løssl; A Zedeler; M L Grøndahl Journal: J Assist Reprod Genet Date: 2020-09-18 Impact factor: 3.412